Skip to content
10-Q

Quarterly Report

Oncternal Therapeutics, Inc.

0000950170-24-057008

← back to feed
Filed
May 9, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 2, 2024 2.96M sh
Shares Diluted Q1 2024 · Mar 31, 2024 2.96M sh
Shares Diluted restated Q1 2024 · Mar 31, 2023 2.93M sh
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$7.44M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$10.97M
Short Term Investments Q1 2024 · Mar 31, 2024 $20.63M
Short Term Investments Q1 2024 · Dec 31, 2023 $27.56M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $6.4M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $6.7M
Stockholders Equity Q1 2024 · Mar 31, 2024 $22.93M
Stockholders Equity Q1 2024 · Dec 31, 2023 $30.05M
Stockholders Equity Q1 2024 · Mar 31, 2023 $52.49M
Stockholders Equity Q1 2024 · Dec 31, 2022 $60.97M
Current Liabilities Q1 2024 · Mar 31, 2024 $6.12M
Current Liabilities Q1 2024 · Dec 31, 2023 $5.2M
Total Liabilities Q1 2024 · Mar 31, 2024 $6.22M
Total Liabilities Q1 2024 · Dec 31, 2023 $6.68M
Current Assets Q1 2024 · Mar 31, 2024 $28.5M
Current Assets Q1 2024 · Dec 31, 2023 $36.06M
Total Assets Q1 2024 · Mar 31, 2024 $29.14M
Total Assets Q1 2024 · Dec 31, 2023 $36.73M
Eps Diluted Q1 2024 · Mar 31, 2024 −$2.83
Eps Diluted restated Q1 2024 · Mar 31, 2023 −$3.93
Eps Basic Q1 2024 · Mar 31, 2024 −$2.83
Eps Basic restated Q1 2024 · Mar 31, 2023 −$3.93
Net Income Q1 2024 · Mar 31, 2024 −$8.39M
Net Income Q1 2024 · Mar 31, 2023 −$11.49M
Operating Income Q1 2024 · Mar 31, 2024 −$8.78M
Operating Income Q1 2024 · Mar 31, 2023 −$12.14M
Revenue Q1 2024 · Mar 31, 2024 $569K
Revenue Q1 2024 · Mar 31, 2023 $203K